Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
暂无分享,去创建一个
Suzanne F. Jones | H. Burris | J. Infante | K. Pierce | J. Jakubczak | P. Schöffski | Huiping Xu | H. Dumez | C. Fowst | P. Gerletti | Elke Van Mieghem | P. English